Terapevticheskii arkhiv · 2006
[Effects of atorvastatin and acipimox on the lipid spectrum of blood plasma, endothelial function and a clinical course of unstable angina pectoris].
Клиническое исследованиеСравнительное исследованиеСтатьяНазвание и аннотация: Оригинал на русском
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kurbanov R D, Shek A B, Tashkenbaeva N F
Аннотация
AIM: Assessment of effects of a 3-month course of atorvastatin and a nicotinic acid derivative acipimox on the lipid spectrum, platelet aggregation, results of brachial artery reactive hyperemia test and clinical outcomes in patients with unstable angina pectoris (UAP).
MATERIAL AND METHODS: A total of 109 males with new-onset and progressive UAP entered the trial. They had LDLP cholesterol > or = 115 mg/dl.
RESULTS: The addition of atorvastatin to combined therapy of UAP patients resulted in achievement of a target level of LDLP cholesterol level in 64% dose-adjusted patients while in acipimox patients the target level was achieved in 20% patients. In spite of a more potent effect on endothelial function, acipimox had an insignificant effect on the treatment outcomes.
CONCLUSION: Hypolipidemic therapy with atorvastatin and acipimox for UAP leads to a significant reduction in LDLP cholesterol. The effect of atorvastatin comes much earlier and more frequently provides a target level of LDLP cholesterol.
MATERIAL AND METHODS: A total of 109 males with new-onset and progressive UAP entered the trial. They had LDLP cholesterol > or = 115 mg/dl.
RESULTS: The addition of atorvastatin to combined therapy of UAP patients resulted in achievement of a target level of LDLP cholesterol level in 64% dose-adjusted patients while in acipimox patients the target level was achieved in 20% patients. In spite of a more potent effect on endothelial function, acipimox had an insignificant effect on the treatment outcomes.
CONCLUSION: Hypolipidemic therapy with atorvastatin and acipimox for UAP leads to a significant reduction in LDLP cholesterol. The effect of atorvastatin comes much earlier and more frequently provides a target level of LDLP cholesterol.